CANaDian Evaluation of Low DosE Infliximab in Ankylosing Spondylitis

Trial Profile

CANaDian Evaluation of Low DosE Infliximab in Ankylosing Spondylitis

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Infliximab (Primary)
  • Indications Ankylosing spondylitis
  • Focus Therapeutic Use
  • Acronyms CANDLE
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 03 Apr 2017 Last checked against ClinicalTrials.gov record.
    • 01 May 2010 MRI results published in the Journal of Rheumatology.
    • 15 Mar 2010 Results published in the Journal of Rheumatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top